ST Spyre Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Track the Spyre Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €8bn. The latest transaction was disclosed on 3 September 2026 (Levée d'options). Among the most active insiders: Burrows Scott L. All data is free.
Analyst consensus: bullish or bearish? Analysts rate Spyre Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$119.71.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
All Executives80 Thresholds0 Prospectus0 Other0
Declarations 80 total
◇ Chief Financial Officer · Executives · 1 Sept 2026
7,500 shares @ US$14.50 Common Stock SEC:0001636282-26-000109:0
▼ Chief Financial Officer · Executives · 1 Sept 2026
900 shares @ US$86.25 Common Stock SEC:0001636282-26-000109:1
▼ Chief Financial Officer · Executives · 1 Sept 2026
4,384 shares @ US$87.11 Common Stock SEC:0001636282-26-000109:2
▼ Chief Financial Officer · Executives · 1 Sept 2026
2,016 shares @ US$88.03 Common Stock SEC:0001636282-26-000109:3
▼ Chief Financial Officer · Executives · 1 Sept 2026
200 shares @ US$89.04 Common Stock SEC:0001636282-26-000109:4
▼ Chief Financial Officer · Executives · 2 Sept 2026
18,232 shares @ US$89.35 Common Stock SEC:0001636282-26-000109:5
◇ See Remarks · Executives · 1 Sept 2026
27,999 shares @ US$14.50 Common Stock SEC:0001636282-26-000111:0
▼ See Remarks · Executives · 1 Sept 2026
4,845 shares @ US$86.40 Common Stock SEC:0001636282-26-000111:1
▼ See Remarks · Executives · 1 Sept 2026
16,548 shares @ US$87.20 Common Stock SEC:0001636282-26-000111:2
▼ See Remarks · Executives · 1 Sept 2026
6,206 shares @ US$88.17 Common Stock SEC:0001636282-26-000111:3
▼ See Remarks · Executives · 1 Sept 2026
400 shares @ US$89.38 Common Stock SEC:0001636282-26-000111:4
◇ See Remarks · Executives · 2 Sept 2026
400 shares @ US$14.50 Common Stock SEC:0001636282-26-000111:5
▼ See Remarks · Executives · 2 Sept 2026
400 shares @ US$90.00 Common Stock SEC:0001636282-26-000111:6
◇ Director · Executives · 7 Aug 2026
5,000 shares @ US$10.39 0.0006% mcap 1.9% of flow Common Stock SEC:0001636282-26-000102:0
▼ Director · Executives · 7 Aug 2026
5,000 shares @ US$104.47 0.0057% mcap 19.2% of flow Common Stock SEC:0001636282-26-000102:1
▼ Director · Executives · 7 Aug 2026
10,000 shares @ US$104.68 0.012% mcap 38.4% of flow Common Stock SEC:0001636282-26-000102:3
▼ Director · Executives · 7 Aug 2026
8,000 shares @ US$104.38 0.0092% mcap 30.6% of flow Common Stock SEC:0001636282-26-000102:2
▼ Chief Executive Officer · Executives · 3 Aug 2026
1,392 shares @ US$96.82 0.0016% mcap 2.8% of flow Common Stock SEC:0001636282-26-000099:3
▼ Chief Executive Officer · Executives · 3 Aug 2026
800 shares @ US$93.97 0.0009% mcap 1.6% of flow Common Stock SEC:0001636282-26-000099:0
◇ Chief Financial Officer · Executives · 3 Aug 2026
7,500 shares @ US$14.50 0.0013% mcap 3.3% of flow Common Stock SEC:0001636282-26-000100:0
▼ Chief Financial Officer · Executives · 3 Aug 2026
5,100 shares @ US$95.21 0.0059% mcap 14.6% of flow Common Stock SEC:0001636282-26-000100:1
▼ Chief Financial Officer · Executives · 3 Aug 2026
2,300 shares @ US$96.30 0.0027% mcap 6.7% of flow Common Stock SEC:0001636282-26-000100:2
▼ Chief Financial Officer · Executives · 3 Aug 2026
100 shares @ US$97.10 0.0001% mcap 0.3% of flow Common Stock SEC:0001636282-26-000100:3
▼ Chief Executive Officer · Executives · 3 Aug 2026
7,157 shares @ US$95.10 0.0083% mcap 14.1% of flow Common Stock SEC:0001636282-26-000099:1
▼ Chief Executive Officer · Executives · 3 Aug 2026
5,635 shares @ US$95.93 0.0066% mcap 11.2% of flow Common Stock SEC:0001636282-26-000099:2
25 of 80 declarations
Load more (55 remaining) Acerca de Spyre Therapeutics, Inc. Spyre Therapeutics, Inc. es una empresa centrada en el desarrollo de terapias innovadoras para enfermedades graves. Cotiza en el mercado XNAS.